Arca
Skip to content
Tools
Tools

GLP1R: Glucagon-like peptide 1 receptor

G protein-coupled receptor for glucagon-like peptide 1 (GLP- 1).

  • Drugs that act on it: 17
  • Approved: 7
  • In phases 1 to 3: 10
  • Sponsors: 12

Who is on it, and how far along

Every drug ChEMBL records acting on GLP1R, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1
  • Protein or peptide 16

Approved7

  • Semaglutide
  • Tirzepatide
  • Liraglutide
  • Dulaglutide
  • Exenatide
  • Lixisenatide
  • Albiglutide

Phase 35

  • Survodutide
  • Retatrutide
  • Avexitide
  • Efpeglenatide
  • Taspoglutide

Phase 25

  • Cotadutide
  • Danuglipron
  • Efinopegdutide
  • Pegapamodutide
  • Pegsebrenatide

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 16 of 17 act as: Glucagon-like peptide 1 receptor agonist; the rest name their own mechanism.
    SemaglutideBoxed warningApprovedNovo NordiskProtein or peptideAgonist380
    TirzepatideBoxed warningApprovedEli LillyProtein or peptideAgonist214
    LiraglutideBoxed warningApprovedNovo NordiskProtein or peptideAgonist48
    DulaglutideBoxed warningApprovedEli LillyProtein or peptideAgonist25
    ExenatideBoxed warningApprovedAstraZeneca PharmaceuticalsProtein or peptideAgonist20
    LixisenatideApprovedSanofiProtein or peptideAgonist8
    AlbiglutideBoxed warningApprovedGSKProtein or peptideAgonist2
    SurvodutidePhase 3Boehringer Ingelheim PharmaceuticalsProtein or peptideAgonist12
    RetatrutidePhase 3Eli LillyProtein or peptideAgonist11
    AvexitidePhase 3Amylyx PharmaceuticalsProtein or peptideAntagonistGlucagon-like peptide 1 receptor antagonist10
    EfpeglenatidePhase 3SanofiProtein or peptideAgonist0
    TaspoglutidePhase 3RocheProtein or peptideAgonist0
    CotadutidePhase 2AstraZeneca PharmaceuticalsProtein or peptideAgonist0
    DanuglipronPhase 2PfizerSmall moleculeAgonist0
    EfinopegdutidePhase 2Johnson & JohnsonProtein or peptideAgonist0
    PegapamodutidePhase 2OPKO HealthProtein or peptideAgonist0
    PegsebrenatidePhase 2Neuraly, Inc.Protein or peptideAgonist0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 58 in all, from ClinicalTrials.gov.
    Semaglutide Effects on Sperm Concentration in Overweight Infertile MenSemaglutidePhase 2Not yet recruitingCopenhagen University Hospital at HerlevNov 18, 2026
    Tirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial HypertensionTirzepatidePhase 2Not yet recruitingBrigham and Women's HospitalNov 18, 2026
    A Research Study Investigating How a New Medicine NNC0721-5186 Works in Women Living With Overweight or ObesitySemaglutidePhase 1Not yet recruitingNovo Nordisk A/SNov 17, 2026
    Fighting Osteoporosis With Risedronate Co-Therapy During IncretinTirzepatidePhase 3Not yet recruitingWake Forest University Health SciencesNov 17, 2026
    A Study to Compare How Survodutide is Taken up by the Body When Given in 2 Formulations to People With Overweight or ObesitySurvodutidePhase 1Not yet recruitingBoehringer IngelheimNov 16, 2026
    Safety and Pharmacokinetics of UI112 Compared With UIC202611 in Healthy AdultsSemaglutidePhase 1Not yet recruitingKorea United Pharm. Inc.Nov 13, 2026
    A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or BothSemaglutidePhase 3Not yet recruitingNovo Nordisk A/SNov 12, 2026
    AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or BothSemaglutidePhase 3Not yet recruitingNovo Nordisk A/SNov 12, 2026
    Molecular and Microbiome Changes During Tirzepatide Treatment and Resistance Training in ObesityTirzepatide—Not yet recruitingTechnical University of MunichNov 12, 2026
    Breath Acetone During Tirzepatide Treatment and Resistance Training in Adults With ObesityTirzepatide—Not yet recruitingTechnical University of MunichNov 12, 2026
    24-hour Clear Liquid Diet vs. Standard Fasting for Upper Gastrointestinal Endoscopy in Patients Taking Agonists of the GLP-1 ReceptorDulaglutide, Liraglutide, Semaglutide, TirzepatideNot applicableNot yet recruitingPortuguese Oncology Institute, CoimbraNov 10, 2026
    Functional, Cognitive, and Behavioral Correlates of Resistance Training During Tirzepatide-Induced Weight LossTirzepatide—Not yet recruitingTechnical University of MunichNov 10, 2026
    Exercise and Protein to Reduce Muscle Loss During GLP-1-Based Treatment in Type 2 DiabetesSemaglutide, TirzepatideNot applicableNot yet recruitingGerman Diabetes CenterNov 9, 2026
    Ocular Changes in Patients Using Tirzepatide or SemaglutideSemaglutide, Tirzepatide—RecruitingIstanbul UniversityNov 9, 2026
    Changes in Body Composition Following Pharmacological Treatment for Obesity.Liraglutide—Enrolling by invitationHospital San Carlos, MadridNov 2, 2026
    A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney DiseaseExenatide, Liraglutide, LixisenatidePhase 2Active, not recruitingBeijing University of Chinese MedicineOct 30, 2026
    Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults With ObesityLiraglutide—RecruitingYuzuncu Yil UniversityOct 28, 2026
    A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapyDulaglutide, Exenatide, Liraglutide, Lixisenatide—Not yet recruitingNovartis PharmaceuticalsOct 19, 2026
    Hypothalamic GLP-1 Response in Healthy Weight and ObesityAvexitideNot applicableRecruitingUniversity of CopenhagenOct 2, 2026
    SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightSurvodutidePhase 3RecruitingBoehringer IngelheimOct 2, 2026
    ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver DiseaseSurvodutidePhase 3Not yet recruitingBoehringer IngelheimSep 30, 2026
    SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose WeightSurvodutidePhase 3RecruitingBoehringer IngelheimSep 30, 2026
    Comparison of [68Ga]Ga-HBED-CC-PEG6-Exendin-4 and [68Ga]Ga-HBED-CC-Exendin-4 PET/CT for Insulinoma LocalizationExenatideNot applicableRecruitingPeking Union Medical College HospitalSep 9, 2026
    Islet Function in Gestational DiabetesAvexitidePhase 1RecruitingMayo ClinicSep 8, 2026
    GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF RegistryDulaglutide, Liraglutide—Not yet recruitingMiedziowe Centrum Zdrowia SAAug 26, 2026
    A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or ObesitySurvodutidePhase 1Active, not recruitingBoehringer IngelheimAug 17, 2026
    A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood SugarSurvodutidePhase 3RecruitingBoehringer IngelheimAug 10, 2026
    Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor AgonistsDulaglutide, Exenatide, Liraglutide—RecruitingOhio State UniversityJul 14, 2026
    Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes MellitusDulaglutidePhase 2Not yet recruitingProGen. Co., Ltd.Jul 1, 2026
    A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesDulaglutidePhase 3RecruitingEli Lilly and CompanyJun 25, 2026
    Estimating the Impact of Obesity Medications on Clinical and Economic OutcomesLiraglutide—Enrolling by invitationIndiana UniversityJun 10, 2026
    Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney DiseaseDulaglutidePhase 4Not yet recruitingFirst Affiliated Hospital of Wannan Medical CollegeApr 17, 2026
    Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple SclerosisExenatidePhase 2RecruitingJohns Hopkins UniversityMar 27, 2026
    Effect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are OverweightRetatrutidePhase 2RecruitingHudson BiotechMar 12, 2026
    A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the BodySurvodutidePhase 1Active, not recruitingBoehringer IngelheimFeb 12, 2026
    A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or OverweightRetatrutidePhase 3Active, not recruitingEli Lilly and CompanyJan 22, 2026
    A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes MellitusExenatideEarly phase 1RecruitingThe First Affiliated Hospital of Henan University of Science and TechnologyJan 16, 2026
    Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor AgonistsDulaglutidePhase 4Active, not recruitingMaryAnn BanerjiJan 8, 2026
    Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKDExenatide—RecruitingCardenal Herrera UniversityDec 30, 2025
    Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral AgentsLixisenatidePhase 4RecruitingShanghai Zhongshan HospitalDec 29, 2025
    A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightRetatrutidePhase 3Active, not recruitingEli Lilly and CompanyNov 18, 2025
    Albuminuria Reduction Study With Survodutide Treatment in Kidney DiseaseSurvodutidePhase 2Not yet recruitingUniversity Medical Center GroningenOct 3, 2025
    Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)Albiglutide, Exenatide, Lixisenatide—Active, not recruitingOhio State UniversitySep 23, 2025
    Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 DiabetesLixisenatidePhase 4Not yet recruitingYanbing LiSep 15, 2025
    A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)RetatrutidePhase 3RecruitingEli Lilly and CompanySep 10, 2025
    Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced DiabetesLixisenatidePhase 4Enrolling by invitationMedical University of WarsawAug 12, 2025
    A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainRetatrutidePhase 3Active, not recruitingEli Lilly and CompanyJun 24, 2025
    POTS-FLOW: Interplay Between Gut Hormones and Autonomic Postprandial Blood Flow Regulation in Patients With POTSAvexitideNot applicableRecruitingUniversity of CopenhagenJun 13, 2025
    A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes MellitusRetatrutidePhase 1Active, not recruitingEli Lilly and CompanyMay 21, 2025
    The Effect of rs7903146 Genotype on Islet GLP-1 Production in HumansAvexitidePhase 2Not yet recruitingMayo ClinicMay 15, 2025
    The Role of Islet GLP-1 in the Pathogenesis of PrediabetesAvexitidePhase 2RecruitingMayo ClinicMay 13, 2025
    The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance.AvexitideNot applicableNot yet recruitingBispebjerg HospitalMar 12, 2025
    A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With ObesityRetatrutidePhase 3Active, not recruitingEli Lilly and CompanyMar 5, 2025
    Avexitide for Treatment of Post-Bariatric HypoglycemiaAvexitidePhase 3Active, not recruitingAmylyx Pharmaceuticals Inc.Dec 24, 2024
    iGlarLixi CGM Study in Chinese T2D Individuals After OADsLixisenatidePhase 4RecruitingSanofiNov 4, 2024
    A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityRetatrutidePhase 3Active, not recruitingEli Lilly and CompanyOct 28, 2024
    Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes StudyAlbiglutide, Lixisenatide—Active, not recruitingBrigham and Women's HospitalFeb 2, 2022
    The Effects of Bariatric Surgeries on Glucose MetabolismAvexitideEarly phase 1RecruitingThe University of Texas Health Science Center at San AntonioJul 6, 2016

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    Type 2 diabetes mellitus
    0.77
    Obesity disorder
    0.72
    Overweight
    0.59
    Hypertensive disorder
    0.55
    Non-alcoholic fatty liver
    0.54
    Type 1 diabetes mellitus
    0.52
    Cirrhosis of liver
    0.46

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1784, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P43220, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.